| Title : The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats - Beckmann_2010_J.Pharmacol.Exp.Ther_335_841 |
| Author(s) : Beckmann JS , Siripurapu KB , Nickell JR , Horton DB , Denehy ED , Vartak A , Crooks PA , Dwoskin LP , Bardo MT |
| Ref : Journal of Pharmacology & Experimental Therapeutics , 335 :841 , 2010 |
| Abstract : Beckmann_2010_J.Pharmacol.Exp.Ther_335_841 |
| ESTHER : Beckmann_2010_J.Pharmacol.Exp.Ther_335_841 |
| PubMedSearch : Beckmann_2010_J.Pharmacol.Exp.Ther_335_841 |
| PubMedID: 20805303 |
Beckmann JS, Siripurapu KB, Nickell JR, Horton DB, Denehy ED, Vartak A, Crooks PA, Dwoskin LP, Bardo MT (2010)
The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats
Journal of Pharmacology & Experimental Therapeutics
335 :841
Beckmann JS, Siripurapu KB, Nickell JR, Horton DB, Denehy ED, Vartak A, Crooks PA, Dwoskin LP, Bardo MT (2010)
Journal of Pharmacology & Experimental Therapeutics
335 :841